cyclin e Search Results


93
ATCC chicken yolk sac endoderm cells
Chicken Yolk Sac Endoderm Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chicken yolk sac endoderm cells/product/ATCC
Average 93 stars, based on 1 article reviews
chicken yolk sac endoderm cells - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

86
Thermo Fisher cyclin e
Cyclin E, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyclin e/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
cyclin e - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier

93
Addgene inc cyclin e promotor
Cyclin E Promotor, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyclin e promotor/product/Addgene inc
Average 93 stars, based on 1 article reviews
cyclin e promotor - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

86
Santa Cruz Biotechnology cyclin e
Irradiated 32D cells arrested in G1 have inactive cyclin E-Cdk2 complexes but retain active Cdk4 and Cdk7. Cell lysates from the 32D-EpoR[H] cultures represented in Fig. ​Fig.1B1B were immunoprecipitated (I.P.) with antibodies to Cdk4, Cdk2, cyclin E, or Cdk7, and in vitro kinase assays were performed (Activity). Immunoprecipitated proteins were Western blotted with Cdk4 antibodies (Cdk4 IP), total and phosphorylation site-specific Cdk2 antibodies (Cdk2 and <t>cyclin</t> <t>E</t> IPs), or Mat1 antibodies (I.P. Cdk7).
Cyclin E, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyclin e/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
cyclin e - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier

90
Addgene inc cyclin e pbi egfp
(A-D) Cells were treated with varying doses of drugs inhibiting cell cycle progression (circles) or protein production (squares). (A) The fold change in cell size (after 44 hrs in drug) vs. fold change in growth rate, relative to untreated cells, is plotted for each condition. Dotted line denotes proportional relationship expected if there is no coordination between growth and cell cycle progression. (B) The fold change in cell size (after 44 hrs in drug) vs. fold change in cell cycle length, relative to untreated cells, is plotted for each condition. (C) Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, calculated from measured increases in bulk protein and number of cells over the course of a 68-hour incubation. Black lines mark iso-cell-size contours. Region between lines spans a 25% shift in cell size. (D) Cells were transfected with plasmids encoding wild-type or degradation-resistant <t>cyclin</t> E under control of a constitutive promoter (diamonds). Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, overlaid on the plot shown in (C). Calculation of the Pearson correlation coefficient between log(growth rate) and log(cell cycle length), using the data shown in (D), yields r = -0.76, p = 2.1x10 −7 , by two-tailed Student’s t-test, indicating a significant inverse correlation between growth rate and cell cycle length. (E,F) Mean growth rate vs. mean cell cycle length for cells treated with drugs inhibiting cell cycle progression (E) or protein production (F), calculated for three time intervals during drug treatment: 0-14 hrs, 14-44 hrs, 44-68 hrs. Lines connect time-points in sequential order, with arrowheads pointing to latest time-point. Data is shown for 25 uM BN82002 (E, green), 1.5 uM Cdk2 Inhibitor III (E, red), 0.06 uM Cycloheximide (F, blue), 10 nM Torin (F, orange), and 7 uM Rapamycin (F, purple). For (A-F), each treatment was done in duplicate, with several thousand cells in each sample.
Cyclin E Pbi Egfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyclin e pbi egfp/product/Addgene inc
Average 90 stars, based on 1 article reviews
cyclin e pbi egfp - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology anti cyclin e1
(A-D) Cells were treated with varying doses of drugs inhibiting cell cycle progression (circles) or protein production (squares). (A) The fold change in cell size (after 44 hrs in drug) vs. fold change in growth rate, relative to untreated cells, is plotted for each condition. Dotted line denotes proportional relationship expected if there is no coordination between growth and cell cycle progression. (B) The fold change in cell size (after 44 hrs in drug) vs. fold change in cell cycle length, relative to untreated cells, is plotted for each condition. (C) Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, calculated from measured increases in bulk protein and number of cells over the course of a 68-hour incubation. Black lines mark iso-cell-size contours. Region between lines spans a 25% shift in cell size. (D) Cells were transfected with plasmids encoding wild-type or degradation-resistant <t>cyclin</t> E under control of a constitutive promoter (diamonds). Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, overlaid on the plot shown in (C). Calculation of the Pearson correlation coefficient between log(growth rate) and log(cell cycle length), using the data shown in (D), yields r = -0.76, p = 2.1x10 −7 , by two-tailed Student’s t-test, indicating a significant inverse correlation between growth rate and cell cycle length. (E,F) Mean growth rate vs. mean cell cycle length for cells treated with drugs inhibiting cell cycle progression (E) or protein production (F), calculated for three time intervals during drug treatment: 0-14 hrs, 14-44 hrs, 44-68 hrs. Lines connect time-points in sequential order, with arrowheads pointing to latest time-point. Data is shown for 25 uM BN82002 (E, green), 1.5 uM Cdk2 Inhibitor III (E, red), 0.06 uM Cycloheximide (F, blue), 10 nM Torin (F, orange), and 7 uM Rapamycin (F, purple). For (A-F), each treatment was done in duplicate, with several thousand cells in each sample.
Anti Cyclin E1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cyclin e1/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
anti cyclin e1 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

93
Proteintech anti herc5
(A-D) Cells were treated with varying doses of drugs inhibiting cell cycle progression (circles) or protein production (squares). (A) The fold change in cell size (after 44 hrs in drug) vs. fold change in growth rate, relative to untreated cells, is plotted for each condition. Dotted line denotes proportional relationship expected if there is no coordination between growth and cell cycle progression. (B) The fold change in cell size (after 44 hrs in drug) vs. fold change in cell cycle length, relative to untreated cells, is plotted for each condition. (C) Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, calculated from measured increases in bulk protein and number of cells over the course of a 68-hour incubation. Black lines mark iso-cell-size contours. Region between lines spans a 25% shift in cell size. (D) Cells were transfected with plasmids encoding wild-type or degradation-resistant <t>cyclin</t> E under control of a constitutive promoter (diamonds). Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, overlaid on the plot shown in (C). Calculation of the Pearson correlation coefficient between log(growth rate) and log(cell cycle length), using the data shown in (D), yields r = -0.76, p = 2.1x10 −7 , by two-tailed Student’s t-test, indicating a significant inverse correlation between growth rate and cell cycle length. (E,F) Mean growth rate vs. mean cell cycle length for cells treated with drugs inhibiting cell cycle progression (E) or protein production (F), calculated for three time intervals during drug treatment: 0-14 hrs, 14-44 hrs, 44-68 hrs. Lines connect time-points in sequential order, with arrowheads pointing to latest time-point. Data is shown for 25 uM BN82002 (E, green), 1.5 uM Cdk2 Inhibitor III (E, red), 0.06 uM Cycloheximide (F, blue), 10 nM Torin (F, orange), and 7 uM Rapamycin (F, purple). For (A-F), each treatment was done in duplicate, with several thousand cells in each sample.
Anti Herc5, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti herc5/product/Proteintech
Average 93 stars, based on 1 article reviews
anti herc5 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

93
Addgene inc rc cmv cyclin e plasmid
(A-D) Cells were treated with varying doses of drugs inhibiting cell cycle progression (circles) or protein production (squares). (A) The fold change in cell size (after 44 hrs in drug) vs. fold change in growth rate, relative to untreated cells, is plotted for each condition. Dotted line denotes proportional relationship expected if there is no coordination between growth and cell cycle progression. (B) The fold change in cell size (after 44 hrs in drug) vs. fold change in cell cycle length, relative to untreated cells, is plotted for each condition. (C) Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, calculated from measured increases in bulk protein and number of cells over the course of a 68-hour incubation. Black lines mark iso-cell-size contours. Region between lines spans a 25% shift in cell size. (D) Cells were transfected with plasmids encoding wild-type or degradation-resistant <t>cyclin</t> E under control of a constitutive promoter (diamonds). Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, overlaid on the plot shown in (C). Calculation of the Pearson correlation coefficient between log(growth rate) and log(cell cycle length), using the data shown in (D), yields r = -0.76, p = 2.1x10 −7 , by two-tailed Student’s t-test, indicating a significant inverse correlation between growth rate and cell cycle length. (E,F) Mean growth rate vs. mean cell cycle length for cells treated with drugs inhibiting cell cycle progression (E) or protein production (F), calculated for three time intervals during drug treatment: 0-14 hrs, 14-44 hrs, 44-68 hrs. Lines connect time-points in sequential order, with arrowheads pointing to latest time-point. Data is shown for 25 uM BN82002 (E, green), 1.5 uM Cdk2 Inhibitor III (E, red), 0.06 uM Cycloheximide (F, blue), 10 nM Torin (F, orange), and 7 uM Rapamycin (F, purple). For (A-F), each treatment was done in duplicate, with several thousand cells in each sample.
Rc Cmv Cyclin E Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rc cmv cyclin e plasmid/product/Addgene inc
Average 93 stars, based on 1 article reviews
rc cmv cyclin e plasmid - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

92
ATCC b megaterium
Chronological report of halophilic bacteria and their molecules with antimicrobial activity in vitro against human pathogens.
B Megaterium, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b megaterium/product/ATCC
Average 92 stars, based on 1 article reviews
b megaterium - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

92
Boster Bio polyclonal rabbit anti herc5
Chronological report of halophilic bacteria and their molecules with antimicrobial activity in vitro against human pathogens.
Polyclonal Rabbit Anti Herc5, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal rabbit anti herc5/product/Boster Bio
Average 92 stars, based on 1 article reviews
polyclonal rabbit anti herc5 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology negative control
Chronological report of halophilic bacteria and their molecules with antimicrobial activity in vitro against human pathogens.
Negative Control, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/negative control/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
negative control - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

91
Addgene inc migr1 cyclin e aa
Chronological report of halophilic bacteria and their molecules with antimicrobial activity in vitro against human pathogens.
Migr1 Cyclin E Aa, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/migr1 cyclin e aa/product/Addgene inc
Average 91 stars, based on 1 article reviews
migr1 cyclin e aa - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier

Image Search Results


Irradiated 32D cells arrested in G1 have inactive cyclin E-Cdk2 complexes but retain active Cdk4 and Cdk7. Cell lysates from the 32D-EpoR[H] cultures represented in Fig. ​Fig.1B1B were immunoprecipitated (I.P.) with antibodies to Cdk4, Cdk2, cyclin E, or Cdk7, and in vitro kinase assays were performed (Activity). Immunoprecipitated proteins were Western blotted with Cdk4 antibodies (Cdk4 IP), total and phosphorylation site-specific Cdk2 antibodies (Cdk2 and cyclin E IPs), or Mat1 antibodies (I.P. Cdk7).

Journal:

Article Title: DNA Damage-Induced G 1 Arrest in Hematopoietic Cells Is Overridden following Phosphatidylinositol 3-Kinase-Dependent Activation of Cyclin-Dependent Kinase 2

doi: 10.1128/MCB.21.18.6113-6121.2001

Figure Lengend Snippet: Irradiated 32D cells arrested in G1 have inactive cyclin E-Cdk2 complexes but retain active Cdk4 and Cdk7. Cell lysates from the 32D-EpoR[H] cultures represented in Fig. ​Fig.1B1B were immunoprecipitated (I.P.) with antibodies to Cdk4, Cdk2, cyclin E, or Cdk7, and in vitro kinase assays were performed (Activity). Immunoprecipitated proteins were Western blotted with Cdk4 antibodies (Cdk4 IP), total and phosphorylation site-specific Cdk2 antibodies (Cdk2 and cyclin E IPs), or Mat1 antibodies (I.P. Cdk7).

Article Snippet: Specific proteins were precipitated with 2 μg of antiserum/ml specific for Cdk4 (Santa Cruz C-22), cyclin E (Santa Cruz M-20), or Cdk7 (Santa Cruz M-19) and were used in kinase reactions or for Western blotting.

Techniques: Irradiation, Immunoprecipitation, In Vitro, Activity Assay, Western Blot

Inhibition of PI 3-kinase prevents cytokine treatment from overriding DNA damage-induced inactivation of cyclin E-Cdk2 and expression of p27. (A) 32D-EpoR[wt] cells were synchronized in G0/G1 in the absence of growth factor (No factor). Synchronized cell cultures were supplemented with LY294002 (10 μM) or vehicle control (dimethyl sulfoxide [DMSO]), plus Epo or IL-3. Parallel cultures were then left untreated or exposed to γ irradiation (+ 4 Gy). All cultures were incubated for an additional 24 h prior to analysis by flow cytometry. Values represent the percentage of cells in S phase. (B) Cell lysates prepared from the cultures represented in panel A were immunoprecipitated with Cdk4 or Cdk2 antibodies, and in vitro kinase assays were performed. Alternatively, total cell lysates were Western blotted with antibodies specific for Cdk2 or p27.

Journal:

Article Title: DNA Damage-Induced G 1 Arrest in Hematopoietic Cells Is Overridden following Phosphatidylinositol 3-Kinase-Dependent Activation of Cyclin-Dependent Kinase 2

doi: 10.1128/MCB.21.18.6113-6121.2001

Figure Lengend Snippet: Inhibition of PI 3-kinase prevents cytokine treatment from overriding DNA damage-induced inactivation of cyclin E-Cdk2 and expression of p27. (A) 32D-EpoR[wt] cells were synchronized in G0/G1 in the absence of growth factor (No factor). Synchronized cell cultures were supplemented with LY294002 (10 μM) or vehicle control (dimethyl sulfoxide [DMSO]), plus Epo or IL-3. Parallel cultures were then left untreated or exposed to γ irradiation (+ 4 Gy). All cultures were incubated for an additional 24 h prior to analysis by flow cytometry. Values represent the percentage of cells in S phase. (B) Cell lysates prepared from the cultures represented in panel A were immunoprecipitated with Cdk4 or Cdk2 antibodies, and in vitro kinase assays were performed. Alternatively, total cell lysates were Western blotted with antibodies specific for Cdk2 or p27.

Article Snippet: Specific proteins were precipitated with 2 μg of antiserum/ml specific for Cdk4 (Santa Cruz C-22), cyclin E (Santa Cruz M-20), or Cdk7 (Santa Cruz M-19) and were used in kinase reactions or for Western blotting.

Techniques: Inhibition, Expressing, Irradiation, Incubation, Flow Cytometry, Immunoprecipitation, In Vitro, Western Blot

(A-D) Cells were treated with varying doses of drugs inhibiting cell cycle progression (circles) or protein production (squares). (A) The fold change in cell size (after 44 hrs in drug) vs. fold change in growth rate, relative to untreated cells, is plotted for each condition. Dotted line denotes proportional relationship expected if there is no coordination between growth and cell cycle progression. (B) The fold change in cell size (after 44 hrs in drug) vs. fold change in cell cycle length, relative to untreated cells, is plotted for each condition. (C) Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, calculated from measured increases in bulk protein and number of cells over the course of a 68-hour incubation. Black lines mark iso-cell-size contours. Region between lines spans a 25% shift in cell size. (D) Cells were transfected with plasmids encoding wild-type or degradation-resistant cyclin E under control of a constitutive promoter (diamonds). Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, overlaid on the plot shown in (C). Calculation of the Pearson correlation coefficient between log(growth rate) and log(cell cycle length), using the data shown in (D), yields r = -0.76, p = 2.1x10 −7 , by two-tailed Student’s t-test, indicating a significant inverse correlation between growth rate and cell cycle length. (E,F) Mean growth rate vs. mean cell cycle length for cells treated with drugs inhibiting cell cycle progression (E) or protein production (F), calculated for three time intervals during drug treatment: 0-14 hrs, 14-44 hrs, 44-68 hrs. Lines connect time-points in sequential order, with arrowheads pointing to latest time-point. Data is shown for 25 uM BN82002 (E, green), 1.5 uM Cdk2 Inhibitor III (E, red), 0.06 uM Cycloheximide (F, blue), 10 nM Torin (F, orange), and 7 uM Rapamycin (F, purple). For (A-F), each treatment was done in duplicate, with several thousand cells in each sample.

Journal: bioRxiv

Article Title: Cell size sensing in animal cells coordinates anabolic growth rates with cell cycle progression to maintain uniformity of cell size

doi: 10.1101/123851

Figure Lengend Snippet: (A-D) Cells were treated with varying doses of drugs inhibiting cell cycle progression (circles) or protein production (squares). (A) The fold change in cell size (after 44 hrs in drug) vs. fold change in growth rate, relative to untreated cells, is plotted for each condition. Dotted line denotes proportional relationship expected if there is no coordination between growth and cell cycle progression. (B) The fold change in cell size (after 44 hrs in drug) vs. fold change in cell cycle length, relative to untreated cells, is plotted for each condition. (C) Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, calculated from measured increases in bulk protein and number of cells over the course of a 68-hour incubation. Black lines mark iso-cell-size contours. Region between lines spans a 25% shift in cell size. (D) Cells were transfected with plasmids encoding wild-type or degradation-resistant cyclin E under control of a constitutive promoter (diamonds). Mean growth rate vs. mean cell cycle length are plotted for cells in each condition, overlaid on the plot shown in (C). Calculation of the Pearson correlation coefficient between log(growth rate) and log(cell cycle length), using the data shown in (D), yields r = -0.76, p = 2.1x10 −7 , by two-tailed Student’s t-test, indicating a significant inverse correlation between growth rate and cell cycle length. (E,F) Mean growth rate vs. mean cell cycle length for cells treated with drugs inhibiting cell cycle progression (E) or protein production (F), calculated for three time intervals during drug treatment: 0-14 hrs, 14-44 hrs, 44-68 hrs. Lines connect time-points in sequential order, with arrowheads pointing to latest time-point. Data is shown for 25 uM BN82002 (E, green), 1.5 uM Cdk2 Inhibitor III (E, red), 0.06 uM Cycloheximide (F, blue), 10 nM Torin (F, orange), and 7 uM Rapamycin (F, purple). For (A-F), each treatment was done in duplicate, with several thousand cells in each sample.

Article Snippet: Cyclin E-pBI-EGFP was a gift from Bert Vogelstein (Addgene plasmid # 16654)( Rajagopalan, H. et al.

Techniques: Incubation, Transfection, Control, Two Tailed Test

Chronological report of halophilic bacteria and their molecules with antimicrobial activity in vitro against human pathogens.

Journal: Marine Drugs

Article Title: Halophiles and Their Biomolecules: Recent Advances and Future Applications in Biomedicine

doi: 10.3390/md18010033

Figure Lengend Snippet: Chronological report of halophilic bacteria and their molecules with antimicrobial activity in vitro against human pathogens.

Article Snippet: Sediments of mangrove Nizampatnam, Bay of Bengal, Andhra Pradesh, India , Pseudonocardia endophytica VUK-10 , B. cereus (MTCC 430), S. mutans (MTCC 497), S. aureus (MTCC 3160), S. epidermis (MTCC 120), B. subtilis (ATCC 6633), B. megaterium (NCIM 2187), E. coli (ATCC 35218), P. aeruginosa (ATCC 9027), P. vulgaris (MTCC 7299), S. marcescens (MTCC 118), X. campestris (MTCC 2286), X. malvacearum (NCIM 2954) and S. typhi (ATCC 14028) , N -(4-aminocyclooctyl)-3,5-dinitrobenzamide , C 15 H 20 N 4 O 5 , [ ] .

Techniques: Bacteria, Activity Assay, In Vitro, Saline, Mutagenesis

Promising new compounds derived from halophilic microorganisms candidates for preclinical trials.

Journal: Marine Drugs

Article Title: Halophiles and Their Biomolecules: Recent Advances and Future Applications in Biomedicine

doi: 10.3390/md18010033

Figure Lengend Snippet: Promising new compounds derived from halophilic microorganisms candidates for preclinical trials.

Article Snippet: Sediments of mangrove Nizampatnam, Bay of Bengal, Andhra Pradesh, India , Pseudonocardia endophytica VUK-10 , B. cereus (MTCC 430), S. mutans (MTCC 497), S. aureus (MTCC 3160), S. epidermis (MTCC 120), B. subtilis (ATCC 6633), B. megaterium (NCIM 2187), E. coli (ATCC 35218), P. aeruginosa (ATCC 9027), P. vulgaris (MTCC 7299), S. marcescens (MTCC 118), X. campestris (MTCC 2286), X. malvacearum (NCIM 2954) and S. typhi (ATCC 14028) , N -(4-aminocyclooctyl)-3,5-dinitrobenzamide , C 15 H 20 N 4 O 5 , [ ] .

Techniques: Derivative Assay, Activity Assay